Mentice AB (publ) (MNTC.ST)
SEK 25.3
(1.61%)
SEK 25.3
(1.61%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 163.55 Million SEK | -3.98% |
| 2022 | 170.34 Million SEK | 36.25% |
| 2021 | 125.01 Million SEK | 52.42% |
| 2020 | 82.02 Million SEK | 31.49% |
| 2019 | 62.37 Million SEK | -2.31% |
| 2018 | 63.84 Million SEK | 41.32% |
| 2017 | 45.17 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 163.37 Million SEK | -0.11% |
| 2024 Q2 | 157.91 Million SEK | -3.34% |
| 2023 Q1 | 142.16 Million SEK | -16.54% |
| 2023 Q3 | 141.04 Million SEK | -3.56% |
| 2023 FY | 163.55 Million SEK | -3.98% |
| 2023 Q4 | 163.55 Million SEK | 15.96% |
| 2023 Q2 | 146.25 Million SEK | 2.87% |
| 2022 Q2 | 148.75 Million SEK | 10.1% |
| 2022 FY | 170.34 Million SEK | 36.25% |
| 2022 Q1 | 135.11 Million SEK | 8.08% |
| 2022 Q4 | 170.34 Million SEK | 7.44% |
| 2022 Q3 | 158.54 Million SEK | 6.58% |
| 2021 Q1 | 89.41 Million SEK | 9.02% |
| 2021 Q4 | 125.01 Million SEK | 19.08% |
| 2021 FY | 125.01 Million SEK | 52.42% |
| 2021 Q3 | 104.98 Million SEK | 9.8% |
| 2021 Q2 | 95.61 Million SEK | 6.93% |
| 2020 Q1 | 65.67 Million SEK | 5.28% |
| 2020 FY | 82.02 Million SEK | 31.49% |
| 2020 Q4 | 82.02 Million SEK | 25.49% |
| 2020 Q3 | 65.35 Million SEK | -5.81% |
| 2020 Q2 | 69.39 Million SEK | 5.67% |
| 2019 Q3 | 57.95 Million SEK | -25.35% |
| 2019 Q2 | 77.63 Million SEK | 2.46% |
| 2019 Q1 | 75.77 Million SEK | 18.67% |
| 2019 FY | 62.37 Million SEK | -2.31% |
| 2019 Q4 | 62.37 Million SEK | 7.63% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 FY | 63.84 Million SEK | 41.32% |
| 2018 Q4 | 63.84 Million SEK | 0.0% |
| 2017 FY | 45.17 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -1387.125% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 93.884% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 93.884% |
| Arcoma AB | 33.3 Million SEK | -391.079% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 50.393% |
| BICO Group AB (publ) | 3.26 Billion SEK | 94.99% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 41.567% |
| CellaVision AB (publ) | 212.32 Million SEK | 22.969% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -1052.032% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -2281.066% |
| C-Rad AB (publ) | 122.4 Million SEK | -33.623% |
| Duearity AB (publ) | 17.53 Million SEK | -832.995% |
| Dignitana AB (publ) | 37.56 Million SEK | -335.366% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -726.03% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.338% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -693.94% |
| Iconovo AB (publ) | 14.55 Million SEK | -1023.782% |
| Integrum AB (publ) | 22.07 Million SEK | -640.973% |
| Luxbright AB (publ) | 7 Million SEK | -2236.446% |
| OssDsign AB (publ) | 105.25 Million SEK | -55.385% |
| Paxman AB (publ) | 44.5 Million SEK | -267.463% |
| Promimic AB (publ) | 16.15 Million SEK | -912.342% |
| Qlife Holding AB (publ) | 62.16 Million SEK | -163.08% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -668.653% |
| ScandiDos AB (publ) | 37.18 Million SEK | -339.827% |
| Sectra AB (publ) | 1.64 Billion SEK | 90.035% |
| Sedana Medical AB (publ) | 44.06 Million SEK | -271.191% |
| Senzime AB (publ) | 58.06 Million SEK | -181.674% |
| SpectraCure AB (publ) | 14.97 Million SEK | -992.18% |
| Stille AB | 172.64 Million SEK | 5.263% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 95.541% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 34.726% |